Abstract 2022-RA-1040-ESGO Table 1 Comparison of ovarian function parameters in long-term survivors of Lymphoma patients between baseline (T0) and after 12 months of oral supplementation with Myo-Inositol and D-Chiro-Inositol combined therapy (T12, Group A) abd between baseline (T0) and after 12 months of follow-up without any nutritional supplement (T12, Group B). AMH: anti Müllerian hormone; FSH: follicle-stimulating hormone; LH: luteinizing hormone; PG: progesterone; AFC: antral follicle count

Abstract 2022-RA-1040-ESGO Figure 1 Flow-chart for inclusion and treatment of Long-term Survivors of Lymphoma in the study

Conclusion In our data analysis, comparing ovarian function parameters in group A women between baseline (T0) and after 12 months of oral supplementation with MIC, a significant reduction in FSH and an increase in PG and antral follicle count (AFC) of the right ovary resulted. This result could be due, at least in part, to the known MIC effect on ovulation improvement that contrasts with luteal insufficiency, typical in these patients. The limitations of our study should also be considered, such as the lack of previous similar studies, thus not allowing a direct comparison with other clinical experiences, and the low number of enrolled women. Therefore, further studies are needed to confirm our preliminary findings in a larger setting.

Abstract 2022-RA-1046-ESGO Frequency of bowel anastomosis leakage after modified posterior exenteration – comparison of two surgical methods: classic surgery in patients with ovarian cancer and minimal invasive modified ‘tailored’ technique in deep infiltrating endometriosis patients

Mariusz Kasperski, Krzysztof Nowak, Maja Mrugał, Marcin Kalus, Ewa Miłerowicz – Nibbydzyki, Opolskie Centrum Onkologii, Opole, Poland

Introduction/Background Modified posterior exenteration is procedure performed either during advanced surgical treatment of ovarian cancer and advanced deep infiltrating endometriosis. One of the most severe complications of this procedure is bowel anastomosis leakage.

Methodology Total of 70 patient who underwent modified posterior exenteration (MPE) were enrolled in the study and divided into 2 groups:A: 30 patients treated with laparotomy due to ovarian cancer FIGO IIB – IIICB: 40 patients treated with modified laparoscopic, tailored technique’ (ICG, sealing materials) due to deep infiltrating endometriosis (DIE) [at least 1 lesion in colon, only one segment resected]

Results 1) Average distance of bowel anastomosis from the ‘Z’ line was 90 mm in patients with ovarian cancer vs 75 mm in DIE patients. 2) Average length of resected bowel was similar in both groups. 3) Number of protective stomas was equal: 1 in each group. 4) Bowel anastomosis leakage rate was 10% cases in group A vs 2.5% in group B.

Conclusion In our data analysis, comparing ovarian function parameters in long-term survivors of Lymphoma patients between baseline (T0) and after 12 months of oral supplementation with Myo-Inositol and D-Chiro-Inositol combined therapy (T12, Group A) abd between baseline (T0) and after 12 months of follow-up without any nutritional supplement (T12, Group B). AMH: anti Müllerian hormone; FSH: follicle-stimulating hormone; LH: luteinizing hormone; PG: progesterone; AFC: antral follicle count

Conclusion In our data analysis, comparing ovarian function parameters in long-term survivors of Lymphoma patients between baseline (T0) and after 12 months of oral supplementation with Myo-Inositol and D-Chiro-Inositol combined therapy (T12, Group A) abd between baseline (T0) and after 12 months of follow-up without any nutritional supplement (T12, Group B). AMH: anti Müllerian hormone; FSH: follicle-stimulating hormone; LH: luteinizing hormone; PG: progesterone; AFC: antral follicle count

Conclusion In our data analysis, comparing ovarian function parameters in long-term survivors of Lymphoma patients between baseline (T0) and after 12 months of oral supplementation with Myo-Inositol and D-Chiro-Inositol combined therapy (T12, Group A) abd between baseline (T0) and after 12 months of follow-up without any nutritional supplement (T12, Group B). AMH: anti Müllerian hormone; FSH: follicle-stimulating hormone; LH: luteinizing hormone; PG: progesterone; AFC: antral follicle count

Conclusion In our data analysis, comparing ovarian function parameters in long-term survivors of Lymphoma patients between baseline (T0) and after 12 months of oral supplementation with Myo-Inositol and D-Chiro-Inositol combined therapy (T12, Group A) abd between baseline (T0) and after 12 months of follow-up without any nutritional supplement (T12, Group B). AMH: anti Müllerian hormone; FSH: follicle-stimulating hormone; LH: luteinizing hormone; PG: progesterone; AFC: antral follicle count

Conclusion In our data analysis, comparing ovarian function parameters in long-term survivors of Lymphoma patients between baseline (T0) and after 12 months of oral supplementation with Myo-Inositol and D-Chiro-Inositol combined therapy (T12, Group A) abd between baseline (T0) and after 12 months of follow-up without any nutritional supplement (T12, Group B). AMH: anti Müllerian hormone; FSH: follicle-stimulating hormone; LH: luteinizing hormone; PG: progesterone; AFC: antral follicle count

Conclusion In our data analysis, comparing ovarian function parameters in long-term survivors of Lymphoma patients between baseline (T0) and after 12 months of oral supplementation with Myo-Inositol and D-Chiro-Inositol combined therapy (T12, Group A) abd between baseline (T0) and after 12 months of follow-up without any nutritional supplement (T12, Group B). AMH: anti Müllerian hormone; FSH: follicle-stimulating hormone; LH: luteinizing hormone; PG: progesterone; AFC: antral follicle count

Conclusion In our data analysis, comparing ovarian function parameters in long-term survivors of Lymphoma patients between baseline (T0) and after 12 months of oral supplementation with Myo-Inositol and D-Chiro-Inositol combined therapy (T12, Group A) abd between baseline (T0) and after 12 months of follow-up without any nutritional supplement (T12, Group B). AMH: anti Müllerian hormone; FSH: follicle-stimulating hormone; LH: luteinizing hormone; PG: progesterone; AFC: antral follicle count